On March 4, Sino Biopharmaceutical Limited (1177.HK) announced that it has reached an exclusive licensing agreement with Sanofi for Rovadicitinib, a novel, potent, first-in-class (FIC) oral small-molecule JAK/ROCK inhibitor. 

Welcome to the Rovadicitinib Out-licensing Online Conference Call

● Beijing Time: March 4, 10:30-11:00 AM

● Join Online: https://zoom.us/j/92943799336

● Meeting ID: 92943799336

● Passcode: 117703

Special Reminder: Please ensure your name as a participant is changed to the "Name-Company" format to join the meeting smoothly. 

Under the agreement, CTTQ Pharma, a subsidiary of Sino Biopharmaceutical Limited, grants Sanofi an exclusive license to develop, manufacture, and commercialize Rovadicitinib worldwide. Sino Biopharmaceutical Limited is eligible to receive payments of up to $1.53 billion, including an upfront payment of $135 million and potential development, regulatory, and sales milestone payments, plus tiered royalties up to double digits on annual net sales of Rovadicitinib. The effectiveness of the agreement is subject to customary closing conditions, including obtaining approvals from relevant regulatory authorities. 

The Chairwoman of the Board of Sino Biopharmaceutical Limited stated, "We are delighted to partner with Sanofi to bring this first-in-class JAK/ROCK inhibitor to patients worldwide."This collaboration is a significant milestone in our company's internationalization strategy. Sino Biopharmaceutical Limited has always been committed to becoming the preferred Chinese partner for multinational pharmaceutical companies.""We firmly believe that by leveraging Sanofi's global R&D and commercialization strengths, our company will further accelerate the launch of innovative products and bring more breakthrough therapies to patients globally."

About Rovadicitinib

As a dual-target inhibitor, Rovadicitinib achieves both anti-inflammation and anti-fibrosis effects through synergistic dual-pathway action. On one hand, it targets the JAK/STAT pathway, directly blocking inflammation signal transduction and reducing inflammatory factors produced by myeloid cells at the source. On the other hand, it targets the ROCK pathway, downregulating overactivated T helper 17 (Th17) cells and enhancing regulatory T cell (Treg) function by modulating STAT3/STAT5 phosphorylation, thereby restoring immune balance. 

In February 2026, Rovadicitinib (trade name: Anxu®) was approved for marketing by the National Medical Products Administration (NMPA) of China for the first-line treatment of adult patients with intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythaemia vera myelofibrosis (PPV-MF), or post-essential thrombocythaemia myelofibrosis (PET-MF). 

In addition, Rovadicitinib has shown breakthrough potential in the treatment of chronic graft versus host disease (cGVHD): it has entered Phase III clinical trial stage in China and was included in the Breakthrough Therapy Designation (BTD) program by the Center for Drug Evaluation (CDE), NMPA in August 2025; it has also been approved to conduct Phase II clinical studies in the United States. Its Phase Ib/IIa clinical data for the treatment of cGVHD have been published in the journal named Blood. The study showed that compared to other approved therapies, Rovadicitinib demonstrated superior 12-month failure-free survival (FFS), stronger therapeutic response in fibrosis-dominant organs, and the potential to overcome ruxolitinib resistance. 

About Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited is a leading innovation and R&D-driven pharmaceutical group in China, with business operations covering the entire industry chain from drug R&D to intelligent manufacturing and commercial sales. Its products include a variety of biologics and chemical drugs, with leading advantages in four core therapeutic areas: neoplasm, liver disease/metabolism, respiratory/autoimmune, and surgery/analgesia. The company has been listed in the "Top 50 Global Pharmaceutical Companies" by the authoritative US magazine Pharmaceutical Executive for seven consecutive years. Adhering to the mission of "Science for a healthier world", Sino Biopharmaceutical Limited continues to provide innovative therapies for patients worldwide, striving to become a leading pharmaceutical company with global competitiveness. 

Source: Announcement published by Sino Biopharmaceutical Limited on the Hong Kong Stock Exchange